Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biosimilar Trends Report

- PMLiVE

Roche blocks Herceptin biosimilar in India

Wins court battle after claiming Biocon and Mylan had not followed regulatory criteria

- PMLiVE

Merck cuts MK-3475 deals with Pfizer, Amgen and Incyte

Sees combination potential for cancer prospect

Sanofi reception

Sanofi sues Lilly over insulin patents

Challenges development of Lantus biosimilar

- PMLiVE

Global biosimilars market “will see exponential growth”

Report predicts market to grow to $23bn by 2019

- PMLiVE

Amgen cholesterol antibody scores in another phase III trial

Evolocumab effective in patients who cannot take statins

- PMLiVE

Biocon plans February launch for first biosimilar Herceptin

Set to market own version of breast cancer drug in India

- PMLiVE

Peacock steps down as Amgen CFO

Michael Kelly appointed acting financial head

- PMLiVE

Amgen throws its hat into the cholesterol antibody ring

Evolocumab set for a race to market with Sanofi/Regeneron and Pfizer

Biogen Idec building

Biogen Idec licenses anti-TNF biosimilars

Treatment prospects emerge from joint venture with Samsung Biologics

- PMLiVE

EMA on track with biosimilars guidance says industry

Updates expected to build confidence among healthcare professionals and patients

Novartis building

Novartis weighs in on biosimilar naming debate

Files petition urging FDA to keep system where biosimilars share a name with the original drug

- PMLiVE

Amgen buys total filgrastim rights from Roche

Wrests control of white blood cell stimulator franchise

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links